Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice

S. Radulovic, A. Nagy, B. Szoke, Andrew V Schally

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Nude mice bearing xenografts of MIA PaCa-2 human pancreatic cancer cell line were treated for 4 weeks with AN-51, a somatostatin octapeptide analog D-Phe-C{A figure is presented}{A figure is presented}s-Thr-NH2(RC-121) containing methotrexate attached to the α-amino group of d-Phe in position 1. Control groups of mice received saline, RC-121 or methotrexate. Drugs were given in equimolar doses by daily s.c. injections. After 7 days of treatment with 25 μg/day of AN-51, tumor growth was completely inhibited although the treatment had to be suspended because of toxic side effects, especially on the gastrointestinal tract, accompanied by major weight loss of the animals. Mice were allowed to recover for 1 week and treatment was continued with 12.5 μg/day AN-51. After 2 weeks of additional therapy, tumor volume, percentage change in tumor volume, and tumor weights were significantly decreased, compared with controls, only in the group treated with AN-51. Methotrexate and RC-121 also inhibited tumor growth, but their effects were not statistically significant. AN-51 retained its hormonal activity and decreased serum growth hormone levels in mice. Binding affinity of AN-51 for somatostatin receptors on MIA PaCa-2 cells was found to be 2.5-times lower than that of parent compound RC-121. This is the first report on inhibition of human pancreatic cancer growth in vivo by somatostatin analogs carrying cytotoxic radicals.

Original languageEnglish
Pages (from-to)263-271
Number of pages9
JournalCancer Letters
Volume62
Issue number3
DOIs
StatePublished - Mar 15 1992
Externally publishedYes

Fingerprint

Somatostatin
Pancreatic Neoplasms
Heterografts
Nude Mice
Methotrexate
Tumor Burden
Growth
Dilatation and Curettage
Somatostatin Receptors
Poisons
Therapeutics
Growth Hormone
Gastrointestinal Tract
Weight Loss
Neoplasms
Cell Line
Control Groups
Injections
RC 121
Serum

Keywords

  • methotrexate
  • pancreatic cancer
  • somatostatin
  • somatostatin analog carrying cytotoxic radical

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. / Radulovic, S.; Nagy, A.; Szoke, B.; Schally, Andrew V.

In: Cancer Letters, Vol. 62, No. 3, 15.03.1992, p. 263-271.

Research output: Contribution to journalArticle

@article{70976bcbf44a4cf9afcef6845b205d2b,
title = "Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice",
abstract = "Nude mice bearing xenografts of MIA PaCa-2 human pancreatic cancer cell line were treated for 4 weeks with AN-51, a somatostatin octapeptide analog D-Phe-C{A figure is presented}{A figure is presented}s-Thr-NH2(RC-121) containing methotrexate attached to the α-amino group of d-Phe in position 1. Control groups of mice received saline, RC-121 or methotrexate. Drugs were given in equimolar doses by daily s.c. injections. After 7 days of treatment with 25 μg/day of AN-51, tumor growth was completely inhibited although the treatment had to be suspended because of toxic side effects, especially on the gastrointestinal tract, accompanied by major weight loss of the animals. Mice were allowed to recover for 1 week and treatment was continued with 12.5 μg/day AN-51. After 2 weeks of additional therapy, tumor volume, percentage change in tumor volume, and tumor weights were significantly decreased, compared with controls, only in the group treated with AN-51. Methotrexate and RC-121 also inhibited tumor growth, but their effects were not statistically significant. AN-51 retained its hormonal activity and decreased serum growth hormone levels in mice. Binding affinity of AN-51 for somatostatin receptors on MIA PaCa-2 cells was found to be 2.5-times lower than that of parent compound RC-121. This is the first report on inhibition of human pancreatic cancer growth in vivo by somatostatin analogs carrying cytotoxic radicals.",
keywords = "methotrexate, pancreatic cancer, somatostatin, somatostatin analog carrying cytotoxic radical",
author = "S. Radulovic and A. Nagy and B. Szoke and Schally, {Andrew V}",
year = "1992",
month = "3",
day = "15",
doi = "10.1016/0304-3835(92)90105-5",
language = "English",
volume = "62",
pages = "263--271",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice

AU - Radulovic, S.

AU - Nagy, A.

AU - Szoke, B.

AU - Schally, Andrew V

PY - 1992/3/15

Y1 - 1992/3/15

N2 - Nude mice bearing xenografts of MIA PaCa-2 human pancreatic cancer cell line were treated for 4 weeks with AN-51, a somatostatin octapeptide analog D-Phe-C{A figure is presented}{A figure is presented}s-Thr-NH2(RC-121) containing methotrexate attached to the α-amino group of d-Phe in position 1. Control groups of mice received saline, RC-121 or methotrexate. Drugs were given in equimolar doses by daily s.c. injections. After 7 days of treatment with 25 μg/day of AN-51, tumor growth was completely inhibited although the treatment had to be suspended because of toxic side effects, especially on the gastrointestinal tract, accompanied by major weight loss of the animals. Mice were allowed to recover for 1 week and treatment was continued with 12.5 μg/day AN-51. After 2 weeks of additional therapy, tumor volume, percentage change in tumor volume, and tumor weights were significantly decreased, compared with controls, only in the group treated with AN-51. Methotrexate and RC-121 also inhibited tumor growth, but their effects were not statistically significant. AN-51 retained its hormonal activity and decreased serum growth hormone levels in mice. Binding affinity of AN-51 for somatostatin receptors on MIA PaCa-2 cells was found to be 2.5-times lower than that of parent compound RC-121. This is the first report on inhibition of human pancreatic cancer growth in vivo by somatostatin analogs carrying cytotoxic radicals.

AB - Nude mice bearing xenografts of MIA PaCa-2 human pancreatic cancer cell line were treated for 4 weeks with AN-51, a somatostatin octapeptide analog D-Phe-C{A figure is presented}{A figure is presented}s-Thr-NH2(RC-121) containing methotrexate attached to the α-amino group of d-Phe in position 1. Control groups of mice received saline, RC-121 or methotrexate. Drugs were given in equimolar doses by daily s.c. injections. After 7 days of treatment with 25 μg/day of AN-51, tumor growth was completely inhibited although the treatment had to be suspended because of toxic side effects, especially on the gastrointestinal tract, accompanied by major weight loss of the animals. Mice were allowed to recover for 1 week and treatment was continued with 12.5 μg/day AN-51. After 2 weeks of additional therapy, tumor volume, percentage change in tumor volume, and tumor weights were significantly decreased, compared with controls, only in the group treated with AN-51. Methotrexate and RC-121 also inhibited tumor growth, but their effects were not statistically significant. AN-51 retained its hormonal activity and decreased serum growth hormone levels in mice. Binding affinity of AN-51 for somatostatin receptors on MIA PaCa-2 cells was found to be 2.5-times lower than that of parent compound RC-121. This is the first report on inhibition of human pancreatic cancer growth in vivo by somatostatin analogs carrying cytotoxic radicals.

KW - methotrexate

KW - pancreatic cancer

KW - somatostatin

KW - somatostatin analog carrying cytotoxic radical

UR - http://www.scopus.com/inward/record.url?scp=0026569101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026569101&partnerID=8YFLogxK

U2 - 10.1016/0304-3835(92)90105-5

DO - 10.1016/0304-3835(92)90105-5

M3 - Article

VL - 62

SP - 263

EP - 271

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 3

ER -